In contrast, another study using a transgenic mouse model of resectable pancreatic ductal adenocarcinoma showed that a mAb targeting the CD96-CD155 interaction (6A6) significantly reduced distant metastases, while a mAb that did not target the CD96-CD155 interaction (8B10) showed no effect on the frequency of metastases (82). Here, CD96 is linked to pancreatic ductal adenocarcinoma.